Barclays
TCRX icon

Barclays’s TScan Therapeutics TCRX Stock Holding History

Barclays’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.8K Buy
19,170
+2,090
+12% +$2.23K ﹤0.01% 4595
2026
Q1 		$17.3K Sell
17,080
-6,116
-26% -$6.54K ﹤0.01% 4604
2025
Q4 		$23.2K Buy
23,196
+4,119
+22% +$5.96K ﹤0.01% 4857
2025
Q3 		$34.7K Sell
19,077
-2,101
-10% -$3.72K ﹤0.01% 4853
2025
Q2 		$30.7K Sell
21,178
-40,672
-66% -$58.8K ﹤0.01% 4785
2025
Q1 		$85.4K Sell
61,850
-5,658
-8% -$12.2K ﹤0.01% 4462
2024
Q4 		$205K Buy
67,508
+9,441
+16% +$42.8K ﹤0.01% 4293
2024
Q3 		$289K Buy
58,067
+44,903
+341% +$271K ﹤0.01% 4108
2024
Q2 		$77K Buy
+13,164
New +$104K ﹤0.01% 4032
2022
Q2 		– Sell
-158,944
Closed -$445K – 5264
2022
Q1 		$445K Buy
+158,944
New +$687K ﹤0.01% 2980

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Barclays's TCRX Position: Q2 2026 in Review

Barclays increased its TScan Therapeutics (TCRX) stake by 12% in Q2 2026, buying an estimated $2.23K and bringing the position to 19,170 shares worth $18.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4595.

Barclays first reported a position in TCRX in Q1 2022 and has held it in 10 quarters since. The position peaked at $445K in Q1 2022. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

  • Barclays held 19,170 shares of TScan Therapeutics worth $18.8K as of Q2 2026.
  • Barclays bought 2,090 TScan Therapeutics shares in Q2 2026, an estimated $2.23K.
  • TScan Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4595 holding.
  • Barclays first reported a position in TScan Therapeutics in Q1 2022 and has held it in 10 quarters since.
  • Barclays's TScan Therapeutics position peaked at $445K in Q1 2022.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.